Diffusion Pharmaceuticals (DFFN) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DFFN shares.
View DFFN analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year price targets for Diffusion Pharmaceuticals' stock. Their DFFN share price forecasts range from $9.50 to $9.50. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for DFFN or view top-rated stocks among Wall Street analysts.

Diffusion Pharmaceuticals' stock was trading at $5.0573 on January 1st, 2023. Since then, DFFN stock has decreased by 25.7% and is now trading at $3.76.
View the best growth stocks for 2023 here.

Diffusion Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 9,700 shares, an increase of 148.7% from the April 30th total of 3,900 shares. Based on an average trading volume of 6,900 shares, the short-interest ratio is currently 1.4 days. Approximately 0.5% of the shares of the stock are short sold.
View Diffusion Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 8th 2023.
View our DFFN earnings forecast.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) posted its earnings results on Wednesday, November, 10th. The company reported ($6.00) EPS for the quarter, missing the consensus estimate of ($2.00) by $4.00.

Shares of Diffusion Pharmaceuticals reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Shares of DFFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DFFN stock can currently be purchased for approximately $3.76.

Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $7.67 million. The company earns $-15,590,000.00 in net income (profit) each year or ($7.65) on an earnings per share basis.

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for the company is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722.